[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636226":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":38,"locations":47,"responsibleParty":58,"collaborators":26,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":26,"enrollmentInfo":70,"targetDuration":26,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":84,"whyStopped":26,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Chonnam National University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Norepinephrine First-Line Vasoactive Drug","EXPERIMENTAL","Participants assigned to this arm will receive norepinephrine as the first-line vasoactive drug for the treatment of cardiogenic shock. The drug will be initiated and titrated according to the protocol-defined dosing algorithm, with adjustments based on hemodynamic response, laboratory values, and clinical status. If participants were receiving vasoactive agents before randomization, norepinephrine will be started at an equivalent protocol-defined dose, and other agents will be tapered as clinically appropriate. All treatment and monitoring will follow current clinical guidelines for cardiogenic shock.",[13],"Drug: Norepinephrine",{"label":15,"type":16,"description":17,"interventionNames":18},"Dopamine First-Line Vasoactive Drug","ACTIVE_COMPARATOR","articipants assigned to this arm will receive dopamine as the first-line vasoactive drug for the treatment of cardiogenic shock. The drug will be initiated and titrated according to the protocol-defined dosing algorithm, with adjustments based on hemodynamic response, laboratory values, and clinical status. If participants were receiving vasoactive agents before randomization, dopamine will be started at an equivalent protocol-defined dose, and other agents will be tapered as clinically appropriate. All treatment and monitoring will follow current clinical guidelines for cardiogenic shock.",[19],"Drug: Dopamine Agent",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Norepinephrine","Norepinephrine will be administered as an intravenous continuous infusion and used as the first-line vasoactive drug for the treatment of cardiogenic shock. The medication will be prepared in standard intensive care unit infusion bags and delivered through a controlled infusion pump. The infusion will be initiated and titrated according to a protocol-defined dosing algorithm, with adjustments based on blood pressure, hemodynamic response, laboratory values, and overall clinical assessment. If a participant was receiving vasoactive agents before randomization, norepinephrine will be started at an equivalent protocol-defined dose, and non-assigned agents will be tapered as clinically appropriate. The duration of infusion will depend on the participant's clinical stabilization. All administration and monitoring will follow current clinical guidelines for cardiogenic shock.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Dopamine Agent","Dopamine will be administered as an intravenous continuous infusion and used as the first-line vasoactive drug for the treatment of cardiogenic shock. The medication will be prepared in standard intensive care unit infusion bags and delivered through a controlled infusion pump. The infusion will be initiated and titrated according to a protocol-defined dosing algorithm, with adjustments based on blood pressure, hemodynamic response, laboratory values, and overall clinical assessment. If a participant was receiving vasoactive agents before randomization, dopamine will be started at an equivalent protocol-defined dose, and non-assigned agents will be tapered as clinically appropriate. The duration of infusion will depend on the participant's clinical stabilization. All administration and monitoring will follow current clinical guidelines for cardiogenic shock.",[15],[32,35],{"name":33,"affiliation":5,"role":34},"Min Chul Kim, Professor, MD, PhD","PRINCIPAL_INVESTIGATOR",{"name":36,"affiliation":5,"role":37},"Min Chul Kin, Professor, MD, PhD","STUDY_CHAIR",[39,43],{"name":33,"role":40,"phone":41,"phoneExt":26,"email":42},"CONTACT","82-10-4606-2643","kmc3242@hanmail.net",{"name":44,"role":40,"phone":45,"phoneExt":26,"email":46},"Yongwhan Lim, Professor, MD","82-10-3229-3392","kalmiarmfl@naver.com",[48],{"facility":5,"status":26,"city":49,"state":26,"zip":50,"country":51,"countryCode":26,"cosmosGeoPoint":52,"geoPoint":57,"contacts":26},"Gwangju","61469","South Korea",{"type":53,"coordinates":54},"Point",[55,56],126.91556,35.15472,{"lat":56,"lon":55},{"type":34,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Min Chul Kim","Professor, MD, PhD","100636226","assessing-catecholamine-treatment-initiation-options-norepinephrine-vs-dopamine-for-cardiogenic-shock-100636226",false,"NCT07562932","Assessing Catecholamine Treatment Initiation Options: Norepinephrine vs Dopamine for Cardiogenic Shock","ACTION-CS","Inclusion Criteria: 1\\&2\n\n1. Age ≥ 19\n2. Cardiogenic shocka in the stage of Society for cardiovascular angiography and intervention (SCAI) C or D\n\n   * Cardiogenic shock was defined as follows, and should fulfill both 1) and 2)\n\n     1. systolic blood pressure \\\u003C90 mm Hg for ≥30 min or need of inotropes or vasopressors to maintain systolic blood pressure \\>90 mm Hg And\n     2. Impaired cardiac function confirmed by cardiac catheterization or echocardiography\n   * Patients will be further classified based on the SCAI shock classification system as follows:\n\n     1. SCAI B: no signs of hypoperfusion\n     2. SCAI C: any signs of hypoperfusion, cardiogenic shock will be classified as SCAI C, and these include mental status change, cool and clammy skin, mottled skin appearance, decreased urine output (30ml\u002Fhour) or lactate over 2.0mmol\u002FL\n     3. SCAI D: requirement of second-line vasoactive drug or mechanical circulatory support based on the predefined treatment protocol\n\nExclusion Criteria: any of these,\n\n1. Administration of vasoactive drug more than 6 hours before enrollment\n2. Patients already on temporary mechanical circulatory supportb before enrollment\n3. Glasgow Coma Scale lower than 8 or other evidence of irreversible brain injury\n4. Shock etiologies other than cardiogenic which include postcardiotomy shock or mixed shock\n5. Pregnancy or lactation","ALL","19 Years",{"count":71,"type":72},512,"ESTIMATED","INTERVENTIONAL",[75],"NA","The goal of this multicenter, open-label, randomized clinical trial is to learn whether norepinephrine or dopamine is more effective and safer as the first-line vasoactive drug for treating cardiogenic shock in adults. Cardiogenic shock is a life-threatening condition in which the heart cannot pump enough blood to supply the body. The main questions this study aims to answer are:\n\nDoes norepinephrine reduce the risk of death or worsening cardiogenic shock compared with dopamine?\n\nDoes norepinephrine lead to fewer complications such as arrhythmias, the need for mechanical circulatory support, or cardiac arrest?\n\nResearchers will compare norepinephrine and dopamine to see which drug better stabilizes blood pressure, improves tissue perfusion, and prevents progression of shock during the early phase of treatment.\n\nParticipants will:\n\nBe randomly assigned to receive either norepinephrine or dopamine as the first vasoactive drug\n\nReceive treatment and monitoring based on current clinical guidelines for cardiogenic shock\n\nUndergo regular assessments of blood pressure, laboratory values, heart rhythm, and organ function during hospitalization\n\nBe followed for outcomes at 1 month, 6 months, and 1 year after enrollment\n\nThis study aims to provide evidence that will help determine which initial vasoactive drug offers better outcomes for patients with cardiogenic shock and guide future treatment recommendations.",[78],"Cardiogenic Shock",[80,23,81,82,83],"Vasoactive drug","Dopamine","Randomized controlled trial","Cardiogenic shock","NOT_YET_RECRUITING","2026-04-28",{"date":87,"type":88},"2026-05-01","ACTUAL",{"date":90,"type":72},"2026-05-31",{"date":92,"type":72},"2032-05-31",{"name":5,"class":6},1]